Premium
Stenotrophomonas (Xanthomonas) maltophilia : A Multidrug‐Resistant Nosocomial Pathogen
Author(s) -
Penzak Scott R.,
Abate Betty J.
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03712.x
Subject(s) - stenotrophomonas maltophilia , microbiology and biotechnology , xanthomonas , pathogen , multiple drug resistance , opportunistic pathogen , antibiotics , antimicrobial , sulfamethoxazole , trimethoprim , stenotrophomonas , biology , antibiotic resistance , pseudomonas aeruginosa , medicine , bacteria , pseudomonas , genetics
Stenotrophomonas (Xanthomonas) maltophilia is emerging as a multidrug‐resistant nosocomial pathogen. In general, the organism is opportunistic, colonizing or infecting patients with predisposing risk factors such intensive care unit residence, malignancy, mechanical ventilation, and previous antibiotic exposure. It can cause a variety of infections depending on underlying patient‐specific medical conditions. It is often part of multimicrobial infections, and determining its role as a pathogen is difficult. Trimethoprim‐sulfamethoxazole (TMP‐SMX) has traditionally been the most active agent against S. maltophilia . Other classes of antibiotics, with few exceptions, have not been effective. Synergistic antimicrobial combinations are now being investigated due to the bacteriostatic nature of TMP‐SMX, and increasing reports of resistance to TMP‐SMX. The combination of ticarcillinclavulanate plus TMP‐SMX appears to be the most promising regimen studied thus far.